Tirzepatide vs Semaglutide: Which Is Right for You?

The Key Difference

Semaglutide (Ozempic/Wegovy) targets one receptor: GLP-1. It's been available longer and has more long-term safety data.

Tirzepatide (Mounjaro/Zepbound) targets two receptors: GLP-1 and GIP. This dual mechanism produces greater weight loss in clinical trials.

Weight Loss Comparison

In the SURMOUNT-5 head-to-head trial:

• Tirzepatide: 20.2% body weight loss at 72 weeks
• Semaglutide: 13.7% body weight loss at 72 weeks

Tirzepatide wins on raw weight loss numbers by a significant margin.

Side Effects

Both share similar GI side effects (nausea, diarrhea, constipation). Tirzepatide may cause slightly more constipation. Semaglutide may cause slightly more nausea. Neither difference is dramatic.

Cost (2026)

Both are similarly priced at $349-499/month self-pay. Insurance coverage varies. Generic liraglutide is the cheapest option at $150-350/month but produces less weight loss (~9%).

Availability

Semaglutide has more approved indications (diabetes, obesity, cardiovascular risk, CKD, MASH). Tirzepatide is approved for diabetes, obesity, and sleep apnea. Both are widely available.

Bottom Line

• Choose tirzepatide if maximum weight loss is your primary goal
• Choose semaglutide if you want the longest safety track record or have cardiovascular/kidney concerns
• Both are excellent options — the "wrong" choice still produces significant results